Weight & metabolism

Liraglutide

Peptilex evidence grade ABCDEUpdated 19 Oct 2026 How grades work

Type: GLP-1 receptor agonist (daily)
Main use or focus: Type 2 diabetes; chronic weight management
Also known as: Victoza, Saxenda

Key studies from the book

3,731 adults, 56 weeks; average weight loss 8.4 kilograms versus 2.8 kilograms on placebo.
SCALE Obesity and Prediabetes – New England Journal of Medicine, 2015
9,340 people with type 2 diabetes and high cardiovascular risk, median 3.8 years; 13 percent fewer heart attacks, strokes or cardiovascular deaths.
LEADER – New England Journal of Medicine, 2016

All key studies, risks and open questions are in the book.

How it works

How the new weight-loss medicines workWhich hormone receptors each one activates

	GLP-1	GIP	Glucagon	Amylin
Liraglutide1×
Semaglutide1×
Tirzepatide2×
Retatrutide3×
CagriSema2×

Source: Peptilex 1, profile overview (type of each peptide)

Research at a glance

Publications by typePubMed, all years

All papers5,683

Human studies3,443

Animal studies only829

Randomized trials561

Meta-analyses & systematic reviews407

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Registered trials by phaseClinicalTrials.gov · name in study title

ongoing / startingcompleted / other

Phase 154

Phase 238

Phase 386

Phase 483

Other48

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Trial starts per yearClinicalTrials.gov · by start date (planned starts included)

262016

122018

92020

42022

122024

12026

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Go deeper

Full profile in the book

What it is, how it acts, the key studies, risks and open questions.

Peptilex – The Peptide Encyclopedia

34 peptides – from semaglutide to BPC-157 – in one book
An evidence grade (A–E) and the key studies for every peptide
Where each one stands in 2026 – US, EU and Switzerland

View on Amazon

Formats: Kindle · Paperback · Hardcover

Amazon store: amazon.com · Change store

Coming soonPeptilex – The Honest GLP-1 HandbookSemaglutide, tirzepatide and the new pills, explained for adults over 50.

Registered trials

ClinicalTrials.gov · name in study title · ongoing first

Study	Phase	Status	Participants	Start
Liraglutide Treatment in Obese Infertile PCOS Women NCT06742710Peking University Third Hospital	Phase 4	Recruiting	890	May 2025
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus NCT06925334Beijing Tsinghua Chang Gung Hospital	Phase 4	Enrolling	170	May 2024
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) NCT03087032The First Affiliated Hospital of Xiamen University	Phase 4	Recruiting	164	Jan 2019
Liraglutide Effect in Atrial Fibrillation NCT03856632University of Miami	Phase 4	Running	60	Mar 2019
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) NCT03883412University of Virginia	Phase 4	Recruiting	60	Feb 2019
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity NCT07590219University of Sao Paulo General Hospital	Phase 4	Running	30	Mar 2024
Saxenda: Underlying Mechanisms and Clinical Outcomes NCT02944500Beth Israel Deaconess Medical Center	Phase 4	Running	28	Nov 2016
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery NCT06361238The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 3	Recruiting	260	Nov 2024
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) NCT07029009Mansa	Phase 2	Recruiting	50	May 2025
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus NCT05268237Biolingus	Phase 1/2	Recruiting	15	Apr 2023

Show 15 moreShow fewer

Study	Phase	Status	Participants	Start
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) NCT07225816Novo Nordisk A/S	Phase 1	Recruiting	71	Nov 2025
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes NCT04324229Turku University Hospital	–	Running	80	Feb 2020
Tirzepatide vs Liraglutide in Bone NCT07094568National and Kapodistrian University of Athens	Observational	Recruiting	72	May 2025
Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity NCT06720246I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	Observational	Recruiting	50	Jun 2024
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. NCT07301437The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Phase 4	Starting soon	120	May 2026
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone NCT06865365Medical University of Vienna	Phase 4	Starting soon	72	May 2025
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes NCT02730377Novo Nordisk A/S	Phase 4	Completed	1,991	Mar 2016
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure NCT01117350Sanofi	Phase 4	Completed	978	Jul 2010
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin NCT01907854Novo Nordisk A/S	Phase 4	Completed	407	Dec 2013
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes NCT01973231Novo Nordisk A/S	Phase 4	Completed	404	Oct 2013
Saxenda in Obesity Services (STRIVE Study) NCT03036800University of Leicester	Phase 4	Completed	392	Nov 2017
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes NCT02008682Novo Nordisk A/S	Phase 4	Completed	368	Dec 2013
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes NCT01917656Novo Nordisk A/S	Phase 4	Completed	343	Jan 2014
Liraglutide Hospital Discharge Trial NCT01919489Emory University	Phase 4	Completed	273	Mar 2014
Impact of Liraglutide 3.0 on Body Fat Distribution NCT03038620University of Texas Southwestern Medical Center	Phase 4	Completed	235	Jan 2017

Showing 25 of 309 matching registered studies. See all on ClinicalTrials.gov.

Latest key papers

PubMed · newest first

2025
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
Meta-analysisGalli M et al. · Journal of the American College of CardiologyPMID 40892610
2025
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
Meta-analysisIsmaiel A et al. · International Journal of ObesityPMID 40804463
2025
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
Meta-analysisBerg S et al. · Obesity ReviewsPMID 40186344
2025
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis
Meta-analysisSouza M et al. · HepatologyPMID 39903735
2025
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Meta-analysisKarakasis P et al. · Metabolism: Clinical and ExperimentalPMID 39719170
2025
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis
Meta-analysisLi M et al. · SleepPMID 39626095
2025
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial
Human RCTPhase 3Fox CK et al. · NEJMPMID 39258838
2024
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Meta-analysisAnsari HUH et al. · Endocrine PracticePMID 38029929

Related peptides

ASemaglutide ATirzepatide BRetatrutide BCagriSema (cagrilintide)APramlintide ASetmelanotide CAOD-9604